Home / Stocks / Sanofi Cons Healthc Ind L
SANOFICONR

Sanofi Cons Healthc Ind L Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹3,494.5

Change

-37.8 (-1.07%)

Open

₹3,495.0

Prev. Close

₹3,532.3

Day High

₹3,533.0

Day Low

₹3,474.1

Volume Analysis

Traded

7,896

Delivered

4,372

Delivery %

55.37%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (2)

  • •Promoter holding is rising
  • •Strong operating margin (35.0%)

Weaknesses (0)

No signal for this stock

Opportunities (1)

  • •Strong 3-year revenue growth (16.5%)

Threats (1)

  • •FII holding has been falling

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹3,585.86 ₹3,559.43 ₹3,526.96 ₹3,500.53 ₹3,468.06 ₹3,441.63 ₹3,409.16
Fibonacci ₹3,559.43 ₹3,536.93 ₹3,523.03 ₹3,500.53 ₹3,478.03 ₹3,464.13 ₹3,441.63
Camarilla ₹3,510.7 ₹3,505.3 ₹3,499.9 ₹3,500.53 ₹3,489.1 ₹3,483.7 ₹3,478.3

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

-23.39%

1 Week

-1.23%

1 Month

+4.1%

3 Months

-17.23%

6 Months

-26.2%

1 Year

-26.37%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

DuPont ROE Breakdown

43.83%

Net margin 27.33% × asset turnover 0.79x × equity multiplier 2.03x

Company Overview

Sector

Healthcare

Source: Screener.in (Consolidated figures) — data as of 20 Nov 2026. Not investment advice.

TopFund Analysis

Sanofi Cons Healthc Ind L holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 78/100. The strongest factor is Financial Strength (100/100), while Institutional Ownership (25/100) is the weakest area to weigh before deciding. Notably: Promoter holding is rising; strong operating margin (35.0%). FII holding has been falling.

TopFund Score — Fundamentals Quality

78/100 — Good

Data confidence: 71/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Growth

83

Cash Flow

87

Corporate Governance

81

Institutional Ownership

25

Business Quality

99

Risk & Volatility

56

Liquidity

41

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Publication of Postal Ballot Notice in the newspapers is enclosed.

Postal ballot dispatched for RPT approvals with Opella India and Opella SAS, up to Rs. 5,301 million by 2027.

Copy of Newspaper Publication of Unaudited Financial Results for the quarter and nine months ended 30th September 2026 is enclosed.

Sanofi Consumer Healthcare India approved Q3 and nine-month FY26 results; Q3 revenue ₹2,631 million, profit ₹1,027 million.

Q3 FY26 revenue rose 12% to ₹2,631 million; nine-month revenue rose 16% to ₹7,280 million.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 (S) Dec 2023 (S) Mar 2024 (S) Jun 2024 (S) Sep 2024 (S) Dec 2024 (S) Mar 2025 (S) Jun 2025 (S) Sep 2025 (S) Dec 2025 (S) Mar 2026 (S) Jun 2026 (S) Sep 2026 (S)
Sales + 210 225 222 172 160 171 173 221 234 251 229 236 263
Expenses + 116 135 140 109 97 109 109 151 149 161 140 146 161
Operating Profit 95 90 82 64 63 62 64 70 85 90 89 89 102
OPM % 45.0% 40.0% 37.0% 37.0% 39.0% 36.0% 37.0% 32.0% 36.0% 36.0% 39.0% 38.0% 39.0%
Other Income + 1 1 3 -24 3 2 5 12 3 5 6 6 4
Interest 0 0 0 0 3 0 0 0 1 0 0 0 0
Depreciation 1 1 1 1 2 1 2 3 3 3 3 3 3
Profit before tax 95 90 84 39 61 63 67 79 84 90 91 92 103
Tax % 25.0% 24.0% 25.0% 25.0% 26.0% 29.0% 25.0% 23.0% 25.0% 27.0% 25.0% 25.0% 25.0%
Net Profit + 71 68 63 29 45 44 50 61 63 66 68 69 77
EPS in Rs — — — 13 20 19 22 26 27 29 29 30 33
Raw PDF — — — — — — — — — — — — —
YoY Sales growth — — — — -24 -24 -22 28 46 47 33 7 12

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Dec 2023 (S) 8m Dec 2024 (S) Mar 2025 (S) Dec 2025 (S)
Sales + 555 724 878 878
Expenses + 337 454 569 569
Operating Profit 219 271 309 309
OPM % 39.0% 37.0% 35.0% 35.0%
Other Income + 2 -15 25 25
Interest 0 4 2 2
Depreciation 2 4 12 12
Profit before tax 219 247 320 320
Tax % 25.0% 27.0% 25.0% 25.0%
Net Profit + 165 181 240 240
EPS in Rs — 79 104 104
Dividend Payout % 6.0% 70.0% 0.0% 72.0%
Sales growth — 30 58 21

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Dec 2023 (S) Dec 2024 (S) Dec 2025 (S) Jun 2026 (S)
Reserves 206 250 361 325
Borrowings + 0 20 25 21
Other Liabilities + 138 138 138 338
Total Liabilities 345 431 547 706
Fixed Assets + 5 29 36 30
CWIP 3 1 0 0
Investments 0 0 0 0
Other Assets + 338 402 511 677
Total Assets 345 431 547 706
Equity Capital 2 23 23 23

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Dec 2023 (S) Dec 2024 (S) Mar 2025 (S) Dec 2025 (S)
Cash from Operating Activity + 0 439 — 175
Cash from Investing Activity + 0 2 — 8
Cash from Financing Activity + 2 -116 — -134
Net Cash Flow 2 325 — 48
Free Cash Flow -4 429 — 167
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 2 208 — 85

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 60.4% → 71.27%
  Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 10.98% 10.56% 9.84% 9.59% 8.59% 8.58% 8.57% 8.41% 8.28% 8.22%
Promoters 60.4% 60.4% 60.4% 60.4% 71.27% 71.27% 71.27% 71.27% 71.27% 71.27%
FII 6.03% 5.22% 4.42% 4.52% 3.24% 2.94% 2.83% 2.76% 2.6% 2.48%
DII 22.6% 23.83% 25.35% 25.48% 16.89% 17.21% 17.33% 17.57% 17.85% 18.03%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Sanofi Cons Healthc Ind L (this stock) — — — —
Sun Pharmaceutical Ind L 451,075 36.7 5.05 16.0%
Divi S Laboratories Ltd 294,139 86.1 16.34 16.5%
Torrent Pharmaceuticals L 177,632 81.8 9.67 27.4%
Apollo Hospitals Enter. L 125,893 55.6 11.86 21.5%
Laurus Labs Limited 125,380 93.6 20.73 18.3%
Zydus Lifesciences Ltd 118,693 26.2 4.27 21.2%

Which Mutual Funds Hold Sanofi Cons Healthc Ind L?

Frequently Asked Questions about Sanofi Cons Healthc Ind L

Community Sentiment

What are other investors saying about Sanofi Cons Healthc Ind L?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.